Saxagliptin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Saxagliptin: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Saxagliptin belongs to the DPP-4 inhibitor (gliptin) drug class, established for type 2 diabetes mellitus treatment. The TxGNN model predicts it may be effective for Opsismodysplasia, a rare skeletal dysplasia, but currently 0 clinical trials and 0 publications support this specific prediction — the score reflects model ranking alone, not clinical or mechanistic evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not provided in regulatory data (Data Gap); inferred as Type 2 Diabetes Mellitus based on drug class (DPP-4 inhibitor), per literature referenced elsewhere in this evidence pack |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 98.09% |
| Evidence Level | L5 |
| EU Market Status | Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for saxagliptin in this evidence pack (flagged as a High-severity data gap, DG002). Based on other literature in this pack (PMID 22071236, a tolerability review of DPP-4 inhibitors), saxagliptin is understood to belong to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, a group of drugs whose established efficacy is in glycemic control for type 2 diabetes mellitus via incretin pathway modulation.
Opsismodysplasia is a rare genetic skeletal dysplasia caused by mutations affecting bone growth signaling, with no established connection to incretin/glucose metabolism pathways. No mechanistic rationale, clinical trial, or literature evidence in this pack links DPP-4 inhibition to opsismodysplasia. This prediction should be treated as a purely computational hypothesis generated by the TxGNN knowledge-graph model, requiring substantial independent validation before any further consideration.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Saxagliptin currently has no EU marketing authorizations recorded in this evidence pack (total_licenses: 0, market status: Not marketed / Not marketed).
Safety Considerations
Please refer to the SmPC for safety information.
(Note: TFDA/regulatory label warnings and contraindications are flagged as a Blocking-severity data gap, DG001 — this must be resolved before any safety evaluation (S1 stage) can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The predicted indication (opsismodysplasia) has zero supporting clinical trials or literature and no plausible mechanistic link identified — this is an L5, model-score-only prediction. Combined with a Blocking-level data gap on safety labeling (DG001) and a High-severity gap on mechanism of action (DG002), there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA/EMA label warnings and contraindications (DG001, Blocking — required before any safety screening)
- Confirmed mechanism of action via DrugBank API (DG002)
- Confirmation of saxagliptin’s original approved indication(s), currently missing from the regulatory dataset
- Independent literature/mechanistic search specifically linking DPP-4 inhibition (or any known saxagliptin pathway) to skeletal dysplasia biology, to assess plausibility before further investment
- If pursuing repurposing evidence more broadly for this drug, note that rank 6 (pancreatic agenesis) currently has 2 supporting literature references and may warrant separate evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.